These substances are related to the DEA’s interest in researching hallucinogenic controlled products for clinical tests and research. The DEA asserts that it wants to support the regulated trials of schedule 1 substances, so increasing the production quota explains why this move is essential. The DEA also wants to research the requirements for manufacturing new drugs and the kind of impact marijuana has on the body. These steps are taken to work towards the Food and Drug Administration’s possibilities to approve a new drug.
The new cannabis beverage boom isn’t really about replacing booze. It’s about replacing everything people…
Amber Senter co-founded Supernova Women, the organization that helped shape America’s first cannabis social equity…
The finding: states that legalized medical or recreational marijuana saw significant reductions in non-fatal opioid…
Eighty-eight percent. Let that sit for a moment. According to the latest nationwide polling from…
A story that once sounded like peak internet fantasy has taken a very real turn. …
Your June 2026 horoscopes brings a powerful mix of growth, reflection, and fresh opportunities. The…